Liver is a primary organ involved in biotransformation of foods and drugs. Liver diseases are a major worldwide problem; Hepatic disorders are mainly caused by toxic chemicals, e.g. - alcohol, carbon tetra chloride, anticancer agent, analgesic, anti-inflammatory drugs, anti-tuberculosis agent and heavy metals. Various risk factors for liver damage include age, gender, alcoholism, nutrition and genetic polymorphisms of cytochrome P₄₅₀ have also been considered. The present review enumerate various hepatic diseases, risk factors and chemicals induced hepatic injury via different mechanical pathway  as well as numerous biochemical changes viz. serum biomarkers, proteomics biomarkers, genomic biomarkers, metabolic biomarkers and micro RNA. This review could be immensely useful for researchers especially for pharmacologists, toxicologist working on hepatotoxicity and drug research organization.

1. Njoku D B. Drug-induced hepatotoxicity: metabolic, genetic and immunological basis. International Journal of Molecular Science 2014; 15(4): 6990-7003.

2. Abboud G, Kaplowitz N. Drug-induced liver injury. Drug Safety 2007; 30: 277-94.

3. Boelsterli UA, Lim PL. Mitochondrial abnormalities--a link to idiosyncratic drug hepatotoxicity. Toxicology and Applied Pharmacology 2007; 220: 92-107

4. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-545

5. Fattovich G, Stroffolini T, Zagni I et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: 35-50.

6. Ganem D, Prince A M. Hepatitis B virus infection—natural history and clinical consequences. The New England Journal of Medicine 2004; 350: 1118-1129.

7. Björnsson E, Angulo P: Non-alcoholic fatty liver disease. The Scandinavian Journal of Gastroenterology 2007; 42:1023-1030.

8. Angulo P. Nonalcoholic Fatty Liver Disease. Mexican Journal of Gastroenterology 2005; 70: 52-56.

9. Farrell G C, Larter C Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: 99-112.

10. Samuel V T, Liu Z X, Qu X et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. The Journal of Biological Chemistry 2014; 279: 32345-32353.

11. Hirschfield G M, Chapman R W, Karlsen T H et al. Reviews in basic and clinical gastroenterology and hepatology. Gastroenterology 2013; 144: 1357–1374.

12. Katarey D, Verma S. Drug_induced liver injury. Clinical Medicine 2016; 16: 104-109.

13. Saadeh S. Nonalcoholic Fatty Liver Disease and Obesity. Nutrition in Clinical Practice 2007; 22: 1-10.

14. Powell E E, Jonsson J R, Clouston A D. Steatosis: co-factor in other liver diseases. Hepatology 2005; 42: 5-13.

15. Björnsson ES, Bergmann O M, Björnsson H et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144: 1419-1425.

16. Lucena M I, Andrade R J, Kaplowitz N et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology 2009; 49: 2001-2009.

17. Fernandez-Liz E, Modamio P, Catalan A et al. Identifying how age and gender influence prescription drug use in a primary healthcare environment in Catalonia, Spain. The British Journal of Clinical Pharmacology 2008; 65:407-417.

18. Devarbhavi H, Dierkhising R, Kremers W K. Anti-tuberculosis therapy drug-induced liver injury and acute liver failure. Hepatology 2010: 52: 798-799.

19. Michikawa T, Inoue M, Sawada N et al. Development of a prediction model for 10-year risk of hepatocellular carcinoma in middle-aged Japanese: the Japan Public Health Center-based Prospective Study Cohort II. Preventive Medicine 2012; 55:137-143.

20. Turati F, Galeone C, Rota M et al. Alcohol and liver cancer: a systematic review and meta-analysis of prospective studies. The Annals of Oncology 2014; 25: 1526-1535.

21. Thomson C A, Wertheim B C, Hingle M et al. Alcohol consumption and body weight change in post menopausal women: results from the Women's Health Initiative. International Journal of Obesity (London) 2012; 36: 1158-1164.

22. Chamorro J G, Castagnino J P, Musella R M et al. Sex, ethnicity, and slow acetylator profile are the major causes of hepatotoxicity induced by antituberculosis drugs. The European Journal of Gastroenterology & Hepatology 2013; 28: 323-328.

23. FDA: Guidance for Industry Drug Interaction Studies — Study Design, Data Analysis, Implications for Dosing, and Labeling. Recommendations http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm

24. Zaccara G, and Perucca E. Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. Epileptic Disorder 2014; 16:409-31.

25. Holecek, M: Ammonia and amino acid profiles in liver cirrhosis: Effects of variables leading to hepatic encephalopathy Nutrition. 2015; 31: 14-20.

26. Singla R, Sharma SK, Mohan A et al. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity. The Indian Journal of Medical Research 2010; 132: 81-86.

27. Neafsey P, Ginsberg G, Hattis D et al. Genetic polymorphism in CYP2E1: Population distribution of CYP2E1activity. Journal of Toxicology and Environmental Health, Part B 2009; 12: 362-388.

28. Vuilleumier N, Rossier M F, Chiappe A et al. CYP2E1genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. The European Journal of Clinical Pharmacology 2006; 62: 423-429.

29. Chalasani N, Fontana R J, Bonkovsky HL et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-1934.

30. Lammert C, Einarsson S, Saha C et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 2008; 47: 2003-2009.

31. Pari L, Karthikesan K. Protective role of caffeic acid against alcohol-induced biochemical changes in rats. Fundamental & Clinical Pharmacology 2007; 21: 355-361.

32. Testino G, Leone S, Borro P. Alcohol and hepatocellular carcinoma: A review and a point of view. World Journal of Gastroenterology 2014; 20:15943-15954.

33. Sheron N, Hawkey C, Gilmore I. Projections of alcohol deaths--a wake-up call. Lancet 2011; 377: 1297-1299.

34. Saravanan S, Pandikumar P, Pazhanivel N et al. Hepatoprotective role of Abelmoschus esculentus (Linn.) Moench, on carbon tetrachloride-induced liver injury. Toxicology Mechanisms and Methods 2013; 23: 528-536.

35. Manibusan M K, Odin M, Eastmond D A. Postulated carbon tetrachloride mode of action: a review. The Journal of Environmental Science and Health, Part C: Environmental Carcinogenesis and Ecotoxicology Reviews 2007; 25: 185-209.

36. Feng Y, Wang N, Ye X et al. Hepatoprotective effect and its possible mechanism of Coptidis rhizoma aqueous extract on carbon tetrachloride-induced chronic liver hepatotoxicity in rats.The Journal of Ethno pharmacology2011; 138: 683-690.

37. Debnath S, Ghosh S, Hazra B. Inhibitory effect of Nymphea pubescens Wild flower extract on carrageenan-induced inflammation and CCl4-induced hepatotoxicity in rats. Food and Chemical Toxicology 2013; 59: 485-491.

38. Bissoli F. Nimesulide-induced hepatotoxicity and fatal hepatic failure. 2008; 49: 436-437.

39. Hussaini S H, Farrington EA. Idiosyncratic drug-induced liver injury: an update on the 2007 overview. Expert Opinion on Drug Safety 2014; 13: 67-81.

40. Unzueta A, Vargas HE. Nonsteroidal anti-inflammatory drug-induced hepatoxicity. Clinical liver Disease 2013; 17: 643-56.

41. Cover C, Liu J, Farhood A et al. Pathophysiological role of the acute inflammatory response during acetaminophen hepatotoxicity. Toxicology and Applied Pharmacology 2006; 216: 98-107.

42. Graham G G, Scott K F, Day R O. Tolerability of paracetamol. Drug Safety 2005; 28: 227-40.

43. Lee T Y, Chang H H, Wen C K et al. Modulation of thioacetamide induced hepatic inflammation, angiogenesis and fibrosis by andrographolide in mice. Journal of Ethnopharmacology 2014; 158: 423-430.

44. Jang Y O, Kim M Y, Cho M Y et al. Effect of bone marrow-derived mesenchymal stem cells on hepatic fibrosis in a thioacetamide-induced cirrhotic rat mode. BMC Gastroenterology 2014; 14: 1-12.

45. Hajovsky H, Hu G, Koen Y et al. Metabolism and toxicity of thioacetamide and thioacetamide S-oxide in rathepatocytes.Chemical Research in Toxicology 2012; 25: 1955-1963.

46. Petit E, Langouet S, Akhdar H et al. Differential toxic effects of azathioprine, 6-mercaptopurine and 6-thioguanine on human hepatocytes. Toxicology In Vitro 2008; 22: 632-642.

47. El-Beshbishy H A, Tork O M, El-Bab M F et al. Antioxidant and antiapoptotic effects of green tea polyphenols against azathioprine-induced liver injury in rats. Pathophysiology 2011; 18: 125-135.

48. Suarez J, Ranguelova K, Jarzecki AA et al. An oxyferrousheme/protein-based radical intermediate is catalytic ally competent in the catalasereaction of Mycobacterium tuberculosis catalase-peroxidase. The Journal of Biological Chemistry 2009; 284: 7017-7029.

49. Saad E I, El-Gowilly S M, Sherhaa M O et al. Role of oxidative stress and nitric oxide in the protective effects of alpha-lipoic acid and aminoguanidine against isoniazid-rifampicin-induced hepatotoxicity in rats. Food and Chemical Toxicology 2010; 48: 1869-1875.

50. Huang Y S, Chern H D, Su W J et al. Cytochrome P450 2E1genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003; 37: 924-930.

51. Strautnieks S S, Bull L N, Knisely A S, Kocoshis SA, Dahl N, Arnell H, Sokal E, Dahan K, Childs S, Ling V, Tanner MS et al. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nature Genetics 1998; 20: 233–238.

52. Faubion W A, Gores GJ. Death receptors in liver biology and pathobiology Hepatology 1999; 29: 1–4.

53. Faubion W A, Guicciardi M E, Miyoshi H et al. Toxic bile salts induce rodent hepatocyte apoptosis via directs activation of Fas. The Journal of Clinical Investigation 1999; 103: 137–145.

54. Miyoshi H, Rust C, Roberts PJ et al. Hepatocyte apoptosis after bile duct ligation in the mouse involves Fas.Gastroenterology1999; 117: 669–677.

55. Amacher D E. Toxicologist's guide to biomarkers of hepatic response. Human & Experimental Toxicology; 2002: 21: 253-262.

56. Ozer J, Ratner M, Shaw M et al. The current state of serum biomarkers of hepatotoxicity. Toxicology 2008; 245: 194-205.

57. Shi L, Wu L L, Yang J R et al. Serum peroxiredoxin3 is a useful biomarker for early diagnosis and assessemnt of prognosis of hepatocellular carcinoma in Chinese patients. The Asian Pacific Journal of Cancer Prevention 2014; 15: 2979-2986.

58. Kim H C, Nam C M, Jee S H et al. Normal serum aminotransferase concentration and risk of mortality from liver disease: prospective cohort study. BMJ 2004; 328: 1-6.

59. Zhao P, Liu W W, Li J F et al. Predictors of liver failure in primary biliary cirrhosis. Upsala Journal of Medical Sciences 2015; 28: 1-5.

60. Wintrobe M M, Greer J P. Wintrobe’s Clinical hematology. Lippincott Williams and Wilkins, 12th edition 2009.

61. Targher G. Elevated serum gamma-glutamyltransferase activity is associated with increased risk of mortality, incident type 2 diabetes, cardiovascular events, chronic kidney disease and cancer - a narrative review. Clinical Chemistry and Laboratory Medicine 2010; 48: 147-157.

62. Geuken E, Visser D, Kuipers F et al. Rapid increase of bile salt secretion is associated with bile duct injury after human liver transplantation. Journal of Hepatology 2004; 41: 1017–1025.

63. Zollner G, Marschall H U, Wagner M et al. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Molecular Pharmaceutics2006; 3: 231–251.

64. Ji C, Wu H, Wei L et al. Proteomic and metabolomic analysis reveal gender-specific responses of mussel Mytilus galloprovincialis to 2,2',4,4'-tetrabromodiphenyl ether (BDE 47).Aquatic Toxicology 2013; 15: 449-457.

65. Mendrick D L, Schnackenberg L.: Genomic and metabolomic advances in the identification of disease and adverse event biomarkers. Biomarkers in Medicine 2009; 3: 605-615.

66. Fitzpatrick E, Dhawan A. Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future. World Journal of Gastroenterology 2014; 20: 10851-10863.

67. Gupta N, Benhamida J, Bhargava Vang J et al. Comparative proteogenomics: combining mass spectrometry and comparative genomics to analyze multiple genomes. Genome Research 2008; 18: 1133-1142.

68. Coen M. Metabolic phenotyping applied to pre-clinical and clinical studies of acetaminophen metabolism and hepatotoxicity. Drug Metabolism Reviews 2015; 23:1-16.

69. Filipowicz W, Bhattacharyya S N, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nature Reviews Genetics 2008; 9: 102-114.

70. Gori M, Arciello M, Balsano C. MicroRNAs in nonalcoholic fatty liver disease: novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma. BioMed Research International 2014; 1-14.

71. Zhang Y, Jia Y, Zheng R et al. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clinical Chemistry 2010; 56: 1830-1838.

72. Baraniskin A, Kuhnhenn J, Schlegel U et al. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood 2011; 117: 3140-3146.

73. Cermelli S, Ruggieri, A, Marrero J A et al. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 2011; 6: 1-8.

74. Roderburg C, Mollnow T, Bongaerts B et al. Micro-RNA profiling in human serum reveals compartment-specific roles of miR-571 and miR-652 in liver cirrhosis. PLoS One 2012; 7: 1-11.

75. Tan Y, Ge G, Pan T et al. A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease. PLoS One 2014; 9: 1-12.

76. Bosetti C, Levi F, Lucchini F et al. Worldwide mortality from cirrhosis: an update to 2002. Journal of Hepatology 2007; 46: 827-839.

77. Mokdad A A, Lopez A D, Shahraz S et al. Liver cirrhosis mortality in 187countries between 1980 and 2010: a systematic analysis. BMC Medicine 2014; 18: 1-24.

78. Vitins A P, Kienhuis A S, Speksnijder E N et al. Mechanisms of amiodarone and valproic acid induced liver steatosis in mouse in vivo act as a template for other hepatotoxicity models. Archives of Toxicology 2014; 88: 1573-1588.

79. Slim R, Fathallah N, Aounallah A et al. Paracetamol-induced Stevens Johnson syndrome and cholestatic hepatitis.Current drug safety 2015; 10: 187-189.

80. Xie Y, Wang G, Wang H. Cytochrome P450 dysregulations in thioacetamide-induced liver cirrhosis in rats and the counteracting effects of hepatoprotective agents. Drug Metabolism and Disposition 2012; 40: 796-802.

81. Dawwas M F, Aithal G P. End-stage methotrexate-related liver disease is rare and associated with features of the metabolic syndrome. Alimentary Pharmacology & Therapeutics 2014; 40: 938-948.

82. Yuan L, Kaplowitz N. Mechanisms of drug-induced liver injury. Clinical Liver Disease 2013;17: 507-518.

83. Al-Halawani M Z, Thawabi M, Asslo F et al. Losartan-induced Ischemic Hepatocellular Hepatotoxicity: A Case Report and Literature Review. Journal of Family Medicine and Prime Care 2014; 3: 272-274.

84. Poli G, Biasi F, Leonarduzzi G. 4-Hydroxynonenal-proteinadducts: A reliable biomarker of lipid oxidation in liver diseases. Molecular Aspects of Medicine 2008; 29: 67-71.

85. Poynard T, Ratziu V, Naveau S et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. See comment in PubMed Commons belowComp. Hepatol 2005; 23: 4-10.

86. Wang X, Zhang A, Han Y et al. Urine metabolomics analysis for biomarker discovery and detection of jaundice syndrome in patients with liver disease. Mol. Cell Proteomics 2012; 11: 370-380.

87. Wang J, Chen, R., Tang, S et al. Interleukin-4 and interleukin-10 polymorphisms and antituberculosis drug-induced hepatotoxicity in Chinese population. Journal of Clinical Pharm Ther 2014; 1-6.

88. El-Meghawry, El-Kenawy A, Osman H E et al. The effect of vitamin C administration on monosodium glutamate induced liver injury. An experimental study. Exp Toxicol Pathol 2013; 65: 513-521.

89. Yang S L, Fang X, Huang Z Z et al. Can serum glypican-3 be a biomarker for effective diagnosis of hepatocellular carcinoma? A meta-analysis of the literature. Dis. Markers 2014; 1-11.

90. Chen R, Wang J, Tang S et al. Association of polymorphisms in drug transporter genes (SLCO1B1 and SLC10A1) and anti-tuberculosis drug-induced hepatotoxicity in a Chinese cohort. Tuberculosis (Edinb). 2014; 1-7.

91. Chen X, Ba Y, Ma L et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Research 2008; 18: 997-1006.

92. Wang Y, Lee A T, Ma JZ et al. Profiling microRNAexpression in hepatocellular carcinoma reveals microRNA-224up-regulation and apoptosis inhibitor-5 as a microRNA-224-specifictarget. J. Biol. Chem 2008; 283: 13205-13215.

93. Yang Y, Fan Y C, Gao S et al. Methylated cysteine dioxygenase-1 gene promoter in the serum is a potential biomarker for hepatitis B virus-related hepatocellular carcinoma. Tohoku J. Exp. Med. 2014; 232: 187-194.

94. Manosuthi W, Sukasem C, Lueangniyomkul A et al. CYP2B6 haplotype and biological factors responsible for hepatotoxicity in HIV-infected patients receiving efavirenz-based antiretroviral therapy. International Journal of Antimicrobial Agents 2014; 43: 292-296.

95. Chen Y J, Zhu J M, Wu H et al. Circulating microRNAs as a Fingerprint for Liver Cirrhosis. PLoS One 2013; 8: 1-9.

96. Mishra S, Daschakraborty S, Shukla P et al. N-acetyltransferase and cytochrome P450 2E1 gene polymorphisms and susceptibility to antituberculosis drug hepatotoxicity in an Indian population. Natl. Med. J. India 2013; 26: 260-265.

97. Li L M, Chen L, Deng G H et al. SLCO1B1 15 haplotype is associated with rifampin-induced liver injury. Molecular Medicine Rep 2012; 6: 75-82.

98. Targher G. Relationship between high-sensitivityC-reactive proteinlevels and liverhistology in subjects with non-alcoholic fatty liver disease. Journal of Hepatology 2006; 45: 879-881

99. Kumar R, Prakash S, Chhabra S et al. Association of pro-inflammatory cytokines, adipokines & oxidative stress with insulin resistance &non-alcoholic fatty liver disease. Indian Journal of Medicinal Research 2012; 136: 229-236.

100. Wang Y, Lee A T, Ma J Z et al. Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224up-regulation and apoptosis inhibitor-5 as a microRNA-224-specifictarget. Journal of Biological Chemistry 2008; 283: 13205-13215.

101. Yamamoto Y, Kosaka N, Tanaka M et al. MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. Biomarkers 2009; 14: 529-538.

102. Huang X H, Wang Q, Chen J S et al. Bead-basedmicroarrayanalysis of microRNA expression in hepatocellular carcinoma: miR-338 is down regulated. Hepatol. Res. 2009; 39: 786-794.

103. Li L M, Hu Z B, Zhou Z X et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Research 2010; 70: 9798-9807.

104. Gui J, Tian Y, Wen X et al. Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clinical Science (Lond). 2011; 120: 183-193.

105. Qi P, Cheng S Q, Wang H et al. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One 2011; 6: 1-8

106. Roderburg C, Luedde M, Vargas C D et al. miR-133a mediates TGF-β-dependent derepression of collagen synthesis in hepatic stellate cells during liver fibrosis. Journal of Hepatology 2013; 58: 736-742.

107. Starkey L PJ, Dear J, Platt V et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 2011; 54: 1767-1776.

108. Xu J, Wu C, Che X et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. 2011; 50:136-142.

109. Zhao P, Liu W W, Li J F et al. Predictors of liver failure in primary biliary cirrhosis. Upsala Journal of Medical Sciences 2015; 28: 1-5.

110. Bihrer V, Friedrich-Rust M, Kronenberger B et al. Serum miR-122 as a biomarker of necro inflammation in patients with chronic hepatitis C virus infection. American Journal of Gastroenterology 2011; 106: 1663-1669.

111. Farid W R, Pan Q, van der Meer A J et al. Hepatocyte-derived microRNAs as serum biomarkers of hepatic injury and rejection after liver transplantation. Liver Transplant 2012; 18: 290-297.

112. Tomimaru Y, Eguchi H, Nagano H et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. Journal of Hepatology 2012; 56: 167-175.

113. Ninomiya M, Kondo Y, Funayama R et al. Distinct microRNAs expression profile in primary biliary cirrhosis and evaluation of miR 505-3p and miR197-3p as novel biomarkers. PLoS One. 2013; 8: 1-11.

114. Shen J, Wang A, Wang Q et al. Exploration of genome-wide circulating microRNA in hepatocellular carcinoma: MiR-483-5p as a potential biomarker. Cancer Epidemiology Biomarkers Preview 2013; 22: 2364-2373.

115. Shrivastava S, Petrone J, Steele R et al. Up-regulation of circulating miR-20a is correlated with hepatitis C virus-mediated liver disease progression. Hepatology 2013; 58: 863-871.

116. Trebicka J, Anadol E, Elfimova N et al. Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. Journal of Hepatology 2013; 58: 234-239.

117. Winther T N, Heiberg I L, Bang-Berthelsen C H et al. Hepatitis B surface antigen quantity positively correlates with plasma levels of microRNAs differentially expressed in immunological phases of chronic hepatitis B in children. PLos One 2013; 8: 1-13.

118. Arataki K, Hayes C N, Akamatsu S, et al. Circulating microRNA-22 correlates with microRNA-122 and represents viral replication and liver injury in patients with chronic hepatitis. British Journal of Medicine and Virology 2013; 85: 789-798.

119. Giray B G, Emekdas G, Tezcan S et al. Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma. Molecular Biology Report 2014; 41: 4513-4519.

120. Kumar S, Chawla Y K, Ghosh S et al. Severity of hepatitis C virus (genotype-3) infection positively correlates with circulating microRNA-122 in patients sera. Dis. Markers 2014; 1-6.

121. Li B K, Huang P Z, Qiu J L et al. Upregulation of microRNA-106b is associated with poor prognosis in hepatocellular carcinoma. Diagn Pathology 2014; 9.

122. Augello C, Gianelli U, Savi F et al. MicroRNA as potential biomarker in HCV-associated diffuse large B-cell lymphoma. Journal of Clinical Pathology 2014; 67: 697-701.